To include your compound in the COVID-19 Resource Center, submit it here.

IPX066: Phase III data

Top-line data from the double-blind, crossover, international Phase III ASCEND-PD trial in 84 evaluable patients with advanced PD showed that IPX066 met the primary endpoint of significantly reducing the percentage of "off" time

Read the full 333 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE